Coreline Soft has renewed its collaboration with Italy’s National Cancer Institute (INT Milano), strengthening its role as a key partner in Europe’s evolving lung cancer screening ecosystem.
The renewed agreement extends the deployment of AVIEW LCS Plus, Coreline’s AI-powered lung cancer screening solution, within Italy’s national screening initiatives. This partnership supports large-scale, multi-center screening operations and reinforces Coreline’s position in public healthcare-driven screening programs.
Supporting Italy’s National Lung Cancer Screening Network (RISP)
The collaboration is closely aligned with RISP (Rete Italiana Screening Polmonare), a nationwide lung cancer screening program led by INT Milano and supported by the Italian Ministry of Health.
RISP connects 18 major hospitals across Italy and is designed to evaluate the effectiveness of low-dose CT (LDCT) screening in high-risk populations. Within this network, Coreline’s AI solution plays a central role by:
• Standardizing imaging data across multiple institutions
• Supporting efficient and consistent interpretation
• Enabling scalable screening operations
This positions AI not only as a diagnostic aid, but as an operational backbone for national screening programs.
From Diagnostic Tool to Screening Infrastructure
The RISP program demonstrates how AI can function as part of a national healthcare system, supported by real-world data from large-scale clinical deployments.
AVIEW LCS Plus enables:
• Automated lung nodule detection
• Quantitative analysis of emphysema and cardiovascular risk factors
• Integrated multi-parameter assessment from LDCT scans
As lung cancer screening programs expand across Europe, operational data generated through initiatives like RISP are expected to inform future reimbursement models and public health policies.
Europe’s Shift Toward Policy-Driven Screening Programs
Across Europe, lung cancer screening is transitioning from pilot programs to structured, policy-driven systems.
In Germany, large-scale studies such as HANSE have demonstrated the clinical and economic value of AI-assisted screening, accelerating national adoption.
In France, national pilot programs such as IMPULSION are expanding with a focus on standardized screening protocols.
At the EU level, lung cancer screening is increasingly prioritized within broader cancer early detection strategies.
This shift reflects a broader trend:
the success of AI in healthcare is no longer defined solely by algorithm performance, but by its ability to operate within national screening infrastructures.
Building Long-Term Infrastructure Through Public Healthcare Partnerships
Coreline Soft’s continued participation in major European screening programs — including RISP, HANSE, IMPULSION, and 4ITLR — highlights its role beyond technology provision.
By working directly with national cancer institutes and public healthcare systems, Coreline is contributing to:
• Standardized screening workflows
• Scalable multi-site operations
• Policy-aligned implementation models
This approach creates a strong foundation for long-term, sustainable growth, as AI becomes embedded in national healthcare systems rather than deployed as standalone tools.
Toward Infrastructure-Level AI in Lung Cancer Screening
Through its European collaborations, Coreline Soft is advancing AI from a diagnostic support tool to a core infrastructure component of lung cancer screening.
This shift reflects a fundamental change in healthcare systems, where AI is integrated into clinical workflows, reimbursement structures, and national policy frameworks.
2026.04.15
List